The Mainz biotech company Biontech will produce significantly more Covid-19 vaccine in 2021 than previously planned. Biontech is now assuming a production capacity of around two billion vaccine doses, the company announced on Monday in an investor presentation. So far, Biontech and its US partner Pfizer had aimed to produce up to 1.3 billion cans by the end of 2021. </p><div> <p>The vaccine manufacturer cited a "continuous improvement of processes" and an expansion of the existing plants as the reason. The new assessment is also based on the fact that more suppliers and contract manufacturers could be won.</p>
Biontech also stated that the new forecast takes into account that six instead of five vaccine doses can now be taken from one vaccination bottle. The European Medicines Agency EMA gave the go-ahead for this last week. This can significantly increase the number of doses to be vaccinated.
By January 10th, 32.9 million doses of the Covid-19 vaccine, which is now approved in more than 45 countries, had been delivered. 50 million cans had been pre-produced by the end of 2020 and ready for delivery after approval. “Since the delivery should take place as needed to ensure correct storage, we have not yet delivered all of the pre-produced cans. That was related to the approvals at the end of December,” explained a Biontech spokeswoman. The delivery schedules were agreed with the countries and the EU.
In the past week, the European Union had secured significantly more doses of the vaccine in view of the persistently high level of new corona infections. The order was doubled by a further 300 million units. The delivery of the additional vaccine doses is planned for the second quarter of 2021.
Source: Apa / Reuters </span> </div>